MedPath

SpyGlass Pharma Completes Phase I/II Trial Enrollment for Glaucoma Drug Delivery Platform

• SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial for a novel drug delivery platform designed to treat glaucoma and ocular hypertension. • The platform delivers bimatoprost over three years during routine cataract surgery, aiming to reduce intraocular pressure (IOP) effectively. • SpyGlass Pharma is preparing to meet with the FDA to discuss advancing its drug delivery platform to Phase III pivotal studies. • The innovative platform could broaden glaucoma treatment during cataract procedures, potentially enhancing adoption among surgeons.

SpyGlass Pharma, a private ophthalmic biotechnology company, announced the completion of enrollment in its Phase I/II clinical trial (NCT06120842) for its novel drug delivery platform targeting glaucoma and ocular hypertension. The platform is designed to deliver bimatoprost over an extended period, aiming to lower intraocular pressure (IOP) in patients undergoing routine cataract surgery.
The SpyGlass Drug Delivery Platform is designed to release bimatoprost over three years to targeted tissues within the eye. The Phase I/II study is a randomized, multi-center, controlled trial evaluating the safety and efficacy of the platform. The company plans to release data from this study, as well as from its first-in-human study, which recently published 18-month data.

Potential Impact on Glaucoma Treatment

"Chronic eye conditions, such as glaucoma, can lead to vision loss and significantly impact quality of life. That’s why SpyGlass is singularly focused on making a difference for those in need," said Patrick Mooney, SpyGlass Pharma’s Chief Executive Officer. He added that completing enrollment in this study is a crucial step in bringing the SpyGlass technology to a wide range of patients. The company anticipates further engagement with the FDA as it moves toward Phase III trials.

Expanding Glaucoma Treatment Options

According to Malik Kahook, M.D., co-founder of SpyGlass Pharma, the technology has the potential to improve care for glaucoma patients undergoing cataract surgery. "As the SpyGlass platform is implanted using standard surgical techniques, it could significantly expand the integration of glaucoma treatment into routine cataract procedures," Dr. Kahook stated. This could lead to broader adoption among surgeons and practices, distinguishing the platform from existing glaucoma interventions.

Future Development

SpyGlass Pharma is preparing for an End of Phase II meeting with the FDA to discuss the requirements for advancing its Drug Delivery Platform into Phase III pivotal studies. The company is backed by investors including New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

SpyGlass Pharma Completes Enrollment in Phase I/II Glaucoma Drug Delivery Study

SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial evaluating its drug delivery platform for glaucoma and ocular hypertension.
The platform delivers bimatoprost over three years and is implanted during routine cataract surgery, potentially expanding glaucoma treatment options.

SpyGlass Pharma Completes Enrollment in Phase I/II Glaucoma Drug Delivery Study

SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial for a novel drug delivery platform targeting glaucoma and ocular hypertension.
The platform delivers bimatoprost over three years, aiming to reduce intraocular pressure (IOP) via a sustained-release mechanism during cataract surgery.

Phaxiam Therapeutics' Phage Therapy Receives FDA Clearance for Phase II PJI Trial

Phaxiam Therapeutics received FDA clearance for its Phase II GLORIA study, evaluating phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial assessing the efficacy of Phaxiam's anti-S. aureus phages in combination with antibiotics for PJI treatment.

FDA Approves Phaxiam Therapeutics' Phase II Trial for Staphylococcus aureus Prosthetic Joint Infections

Phaxiam Therapeutics received FDA approval for its Investigational New Drug (IND) application to conduct a Phase II study, named 'GLORIA', targeting osteoarticular prosthesis infections (PJI) caused by *Staphylococcus aureus*.
The GLORIA study will enroll 100 patients with hip or knee PJI undergoing open surgical debridement (DAIR), evaluating Phaxiam's anti-*S. aureus* phages in combination with antibiotics versus placebo plus antibiotics.

Phaxiam Therapeutics Receives FDA Clearance for Phase II Phage Therapy Study in Prosthetic Joint Infections

Phaxiam Therapeutics received FDA clearance for its Phase II GLORIA study, evaluating phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial that will enroll 100 PJI patients undergoing open surgical debridement.

Phaxiam Therapeutics Receives FDA Clearance for Phase II Phage Therapy Study in Prosthetic Joint Infections

Phaxiam Therapeutics received FDA clearance to begin its Phase II GLORIA study, which will assess phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial evaluating anti-S. aureus phages in combination with antibiotics for PJI patients undergoing open surgical debridement.

Scilex's SP-103 Lidocaine Topical System Receives Positive FDA Feedback for Chronic Neck Pain

Scilex Pharmaceuticals gains FDA agreement on NDA path for SP-103, a triple-strength lidocaine topical system, after a successful Phase II meeting.
SP-103 targets chronic neck pain associated with muscle spasms, with potential peak sales projected at $1.2 billion annually.

Scilex Pharmaceuticals Achieves FDA Agreement on NDA Path for SP-103 in Chronic Neck Pain

Scilex Pharmaceuticals secured FDA agreement on the NDA path for SP-103, a lidocaine topical system 5.4%, following a successful end-of-Phase II meeting.
SP-103, a next-generation, triple-strength formulation of ZTlido, targets chronic neck pain associated with muscle spasms, a market projected to reach $134.5 billion.

Phaxiam Therapeutics Advances Phage Therapy with Phase 2 Trial for Staphylococcus aureus Vascular Graft Infections

Phaxiam Therapeutics' PHAGOSCARPA, a phase 2 study, will assess anti-S. aureus phages for treating extra-cavitary vascular graft implant infections.
The trial, involving 80 patients across 27 French centers, aims to improve outcomes where mortality rates range from 10-25% within 30 days.

Nanoscope Therapeutics to Advance MCO-010 for Stargardt Disease to Phase 3 Trial Following FDA Meeting

Nanoscope Therapeutics' MCO-010 gene therapy is set to advance to a Phase 3 registrational trial for Stargardt Macular Degeneration after a productive meeting with the FDA.
The FDA has provided input on the Phase 3 trial design, which will assess MCO-010's safety and efficacy using best-corrected visual acuity as the primary endpoint.

Reference News

[1]
SpyGlass Pharma Completes Enrollment in Phase I/II Study of - GlobeNewswire
globenewswire.com · Nov 19, 2024

SpyGlass Pharma completes enrollment in Phase I/II trial for its Drug Delivery Platform, designed to deliver bimatoprost...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy